• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

    0.2401 -0.0249 (-9.40%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aspire Biopharma Holdings, Inc. - Common Stock

    Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
    Via ACCESS Newswire
    Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
    Via ACCESS Newswire
    TOMI Environmental (NASDAQ: TOMZ) Expands SteraMist – Protecting People from Germs, Viruses & Biohazards | More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
    Via ACCESS Newswire
    Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
    Via ACCESS Newswire
    Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
    Via ACCESS Newswire
    Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
    Via ACCESS Newswire
    Sidoti Events, LLC's Virtual August Micro-Cap Conference
    Via ACCESS Newswire
    Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20
    Via ACCESS Newswire
    Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc. Announces CEO Transition
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
    Via ACCESS Newswire
    An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
    New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company")... 
    Via Newsfile
    Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
    Via ACCESS Newswire
    Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
    Via ACCESS Newswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.